Compare AGBK & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGBK | DRTS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | Brazil | Israel |
| Employees | 5001 | 121 |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 978.2M |
| IPO Year | N/A | N/A |
| Metric | AGBK | DRTS |
|---|---|---|
| Price | $6.45 | $9.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $17.20 | $8.67 |
| AVG Volume (30 Days) | 414.7K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $235.22 | $699.98 |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $2.87 |
| 52 Week High | $12.21 | $11.62 |
| Indicator | AGBK | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 38.86 | 48.44 |
| Support Level | $6.43 | $6.59 |
| Resistance Level | $7.65 | $11.62 |
| Average True Range (ATR) | 0.36 | 0.95 |
| MACD | -0.05 | -0.21 |
| Stochastic Oscillator | 12.15 | 20.88 |
AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.